A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide Vs. Placebo in Participants With Overweight Or Obesity And Established Cardiovascular Disease
Who can join
Ages 40 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Participants with BMI ≥ 27 kg/m² and established CVD * History of at least one self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * Known history of Type 1 diabetes mellitus * Current or previous treatment with petrelintide or any other amylin analog
About the study
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).
What is being tested
- Petrelintide (combination product)
- Placebo (combination product)
Sponsor: Hoffmann-La Roche · Participants: 2,500 · Started: Sep 30, 2026
Contact the study team
- Reference Study ID Number: CC46446 https://forpatients.roche.com/No attachments to email below. · Phone: 888-662-6728 (U.S. and Canada)
Official record on ClinicalTrials.gov — NCT07843472
Locations in the U.S.
| Alabama | Pinnacle Research Group, Anniston |
| California | Institute for Metabolic Research Los Angeles, Los Angeles |
| Florida | Progressive Medical Research, Port Orange |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.